NEWS

WIRES

OTHER

Tulip BioMed Appoints Kenneth Yonika as CFO

Strong Financial Reporting Background of CPA to Lead Tulip to Fully Reporting Status

Tulip BioMed(TM), Inc. (PINKSHEETS: TPBD), a developer of medical devices and patented technologies for the living tissue markets, including plastic, cosmetic, and orthopedic surgeries, today announces it has appointed Kenneth Yonika as its chief financial officer, effective immediately.

Yonika, a licensed certified public accountant (CPA) and senior finance executive with more than 18 years experience working with publicly traded companies as well as big four accountants and national law firms, has held management responsibility for financial reporting with a billion dollar biotech company as well as several other biotech and high tech start-ups. His broad-based experience includes, in addition to financial and external reporting, initial public offerings, mergers and acquisitions, international business as well as managing operational issues surrounding both logistics and manufacturing. He will assist Tulip BioMed, which is currently a non-reporting publicly traded company, to meet all requirements of the SEC and Sarbanes-Oxley.

For the past year, the company has focused on research and development, and building out its operational and sales infrastructure; with this addition focused efforts will include senior financing and exchange listing. Darin Andersen, president and chief operating officer, said, "With Ken onboard, we feel confident that we can move quickly to become a fully reporting company and eventual listing on one of the national exchanges. We are very pleased that Ken has decided to join the company and its management team."

Previous to Tulip BioMed, Yonika worked with DrugMax, Inc., a publicly traded Connecticut-based national specialty pharmacy and drug distributor, where he served on the senior management team. Prior to his role with DrugMax, Yonika also worked with Carlsbad-based Invitrogen as well as several other public companies in financial and external reporting roles. Yonika is a former big four CPA with ties to national accounting and law firms as well as several investment banks based in Southern California.

About Tulip BioMed, Inc.

Tulip BioMed, Inc. (PINKSHEETS: TPBD) is a Nevada corporation with operations based in San Diego, California. Founded in 2004, Tulip BioMed, Inc. is a medical device, biotechnology company that manufactures and distributes patented technologies for the plastic and cosmetic surgery, biopsy, orthopedic surgery, stem cell therapy and other living tissue markets. Tulip BioMed, Inc. is the exclusive licensee of patented syringe connection devices that use the worldwide recognized Tulip brand name. Tulip BioMed, Inc. manufactures, markets, and distributes medical devices, adapted with these and other patented technologies, to physicians, clinics, military, health organizations, hospitals and other distribution outlets. For more information go to: www.tulipbiomed.com. Products are available for sale at www.tulipdisposable.com.

Safe Harbor: This press release contains certain forward-looking information about Tulip BioMed, Inc., which is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)," and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Tulip BioMed, Inc., that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include: our lack of operating revenue and earnings history, our need for additional capital to pursue our business strategy. We are a non-reporting company and as such do not make periodic filings with the Securities and Exchange Commission. We trade on the Pink Sheets and there can be no assurances that a liquid market will develop in our securities. Readers are cautioned not to place undue reliance on these forward-looking statements. Tulip BioMed, Inc. does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.